The research paper A randomized phase II trial of best supportive care with or without hyperthermia and vitamin C published by Dr. Junwen District, Assistant Dean of Guangdong Clifford Hospital and Deputy Director of Cancer Center, in the well-known comprehensive journal Journal of Advanced Research (IF = 10.479) for heavily pretreated, advanced, refractory non-small-cell lung cancer.
As the first author and corresponding author, Dr. Junwen Au published 3 SCI articles with high concentration of vitamin C, with a total impact factor of 18.142. It was included in top journals such as Journal Of Clinical Oncology and Annals of Oncology in the poster exchanges at international academic conferences, with a total impact factor of 77.52. It shows the reliability, professionalism and authority of the IVC-related research led by Dr. Junwen Au.
High-Concentration Vitc Has Reliable Anti-Tumor Treatment Efficacy
Lung cancer is one of the malignant tumors that seriously threaten human health and life. How to effectively prolong the survival period of patients and improve the quality of life is the focus and research focus of experts and scholars at home and abroad. Although the research on high dosage vitamin c cancer has a long history, it has not been smooth in fact. As early as the 1970s, two-time Nobel Prize winner Pauling proposed that VitC can effectively treat cancer, but it was rejected by the academic community. However, in recent years, studies have found that VitC has different results, mainly because of the different routes of administration and intravenous infusion. Injecting VitC can bypass the intestine and produce a blood concentration 100-500 times higher than oral administration. This “super high” concentration is the key to VitC’s attack on cancer cells. There are constant clinical studies around the world confirming the anti-tumor potential of VitC, which is why VitC has its name rectified.
Junwen Au began to study the safety of IVC against tumors in 2016 . Pharmacokinetic studies suggest that intravenous infusion of VitC (1 g/kg, 1.2 g/kg and 1.5 g/kg) will take two hours in vivo. The peak blood concentration was reached, and no serious adverse reactions occurred, indicating that the application of intravenous VitC infusion is safe in cancer patients.
High Concentration Of Vitc Is Suitable For A Variety Of Pathological Types
Regarding the anti-tumor mechanism of VitC, Dr. Ou explained that after IVC reaches a pharmacological concentration, it can promote hydrogen peroxide to damage tumor cells and cause cancer cell necrosis ; also through up-regulation of tumor suppressor gene P53 and down-regulation of papillary Oncovirus E6 expression , inhibits the DNA synthesis of cancer cells and other forms, interferes with the metabolic cycle of cancer cells, and induces their differentiation and apoptosis .
On the other hand, IVC can enhance the body’s immunity, such as activating T lymphocytes, increasing interleukin-1, downregulating interleukin-6, and inhibiting tumor cell proliferation. Because it can extensively inhibit tumor growth, it is suitable for tumor patients with various pathological types.
Radiofrequency Deep Hyperthermia (Meht) Increases The Peak Vitc Concentration And Doubles Its Effectiveness
The phase II randomized controlled trial in the latest article by Junwen Au enrolled 97 patients with stage IIIB-IV NSCLC who were unresponsive or resistant to chemotherapy, targeted therapy, and immunotherapy. The treatment group was combined with intravenous infusion of high-dose VitC (1 g /kg) and mEHT were treated simultaneously for 25 times, and the control group was given only the best supportive treatment.
Dr. Junwen Au introduced that in clinical use, they found that mEHT can synergize the electric field effect and the thermal effect, localize the mass, release energy in the nanometer range and be absorbed by the cancer cells, the utilization efficiency is increased by 3-4 times, and it can be selectively destroyed. , Kill cancer cells to achieve the purpose of treatment. Due to the short duration of hyperthermia, it is not recommended to use it alone in clinical practice. They found that mEHT can increase the blood concentration of VitC. It shows that the addition of mEHT significantly increases the peak concentration of VitC in patients , further enhancing its anti-tumor effect.
The results of the study by Junwen Au’s team showed that compared with the control group, the quality of life in the combined high-dose VitC and mEHT treatment group was significantly improved, the progression-free survival (PFS) and overall survival (OS) were significantly prolonged, and the 3-month disease control rate Up to 42.9% (only 16.7% in the control group). It is suggested that the combined use of high-dose VitC and mEHT can significantly improve the quality of life of patients with advanced NSCLC and prolong survival.
